Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
Börsentief? Für diesen Geheimtipp scheint das Gegenteil zu gelten
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
139 Leser
Artikel bewerten:
(0)

Derma Fillers Market worth $7.32 billion by 2030 with 12.1% CAGR | MarketsandMarkets

DELRAY BEACH, Fla., June 24, 2025 /PRNewswire/ -- The global Derma Fillers Market, valued at US$3.74 billion in 2024 stood at US$4.13 billion in 2025 and is projected to advance at a resilient CAGR of 12.1% from 2025 to 2030, culminating in a forecasted valuation of US$7.32 billion by the end of the period. The key factors driving the derma fillers market are the demand for non-invasive procedures, social media celebrity influence, technological innovation and advancement, an aging population, rising disposable incomes, and increased interest in personalized treatments.

MarketsandMarkets Logo

Additionally, the rise of medical tourism is, to some extent, a significant driver in the dermal fillers market. Factors such as these play a role in the market's significant expansion and increased usage of dermal fillers globally.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71526267

Browse in-depth TOC on "Derma Fillers Market"

400 - Tables
280 - Figures
320- Pages

By Based on Brand, Allergan (AbbVie Inc.)'s Juvéderm brand has a complete array of hyaluronic acid (HA) dermal fillers to treat many issues, like wrinkle treatment, lip augmentation, and facial contouring. Because of this wide range of indications, practitioners can respond to multiple patient needs within a single brand name. Furthermore, Allergan continues to release new and novel products within the Juvéderm family, such as Juvéderm VOLUX for jawline definition. These continued releases will keep the Juvéderm brand on the cutting edge of clinical practice and patient demands.

As a secondary consideration, Juvéderm products have broad approvals from routinely regulated and trusted agencies in the US FDA and the EU. Likewise, regulatory approval and strong clinical data give both practitioners and patients confidence in using Juvéderm products.

By Based on Product, the natural dermal fillers comprise two subsegments, such as hyaluronic acid fillers and collagen fillers, which are the leading segment of the dermal fillers market. The desire for safe, biocompatible, and natural-appearing cosmetic solutions has led to the development of natural dermal fillers. This desire is driven by social Moore, advances in technology, an ageing population, and the desire for less invasive and reversible procedures. Natural fillers-such as HA-minimally reduce the risk of allergic reactions and other adverse events since they are highly biocompatible and biodegradable. There is a growing acceptance of biodegradable fillers-those that are naturally broken down and absorbed by the body-due to their safety, reversibility, and ability to adjust to the differing needs of patients.

By Based on Procedure, Lip augmentation dominates the derma fillers market, particularly due to the changing beauty standards, social media, technological developments, the government's emphasis on performing minimally invasive procedures, the expanding demographics of customers, product availability and distribution, and increasing disposable income. The biggest motivation for lip augmentation is the desire to create a more balanced face and self-confidence. More interest from younger consumers (Gen Z, millennials) and elderly consumers (who seek rejuvenation) is moving the market base. People's take-home pay is also rising in emerging markets, which allows wealthier people and emerging class individuals to afford more aesthetic procedures. Consumers want fast and effective aesthetic solutions that function within their busy lifestyles. All these factors ultimately work together to reinforce the exceptional growth and continued expansion of the global lip augmentation market.

By geography, the US holds a significant share of the derma fillers market for several important reasons. First, consumers are increasingly looking for ways to rejuvenate their face, reduce wrinkles, and restore volume using minimally invasive options, such as dermal fillers. Consumers opt for dermal fillers instead of surgical procedures because the process can be fast and provide immediate results with less time spent recovering. Additionally, the US consumer has never favored surgical alternatives for the treatment of aging and restoring facial volume and contours, as they do with the options for dermal fillers for non-surgical treatment of the face. Economic growth in the US has allowed its consumers to spend more on elective or cosmetic procedures, driven by a growing number of dual-income households supporting greater purchasing power. The ability to afford to maintain these treatment plans through regular maintenance will drive return visits, resulting in repeat consumer business. These conversations on dermal fillers in the US dermal fillers market are based on a unique combination of demographic trends (aging population), cultural change (impact of social media), technological advancement, economic strength, and improving access to non-invasive cosmetic procedures, which are creating significant growth and widespread acceptance.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=71526267

As of 2024, key players in derma fillers market are Allergan Aesthetics (US), Merz Pharma GmbH & Co. KGaA (Germany), Galderma (Switzerland), Sinclair Pharma (UK), Bioxis Pharmaceutical (France), Suneva Medical (US), Prollenium Medical Technologies (Canada), Croma Pharma (Austria), Zimmer Aesthetics (Germany), Marllor Biomedical (Italy), MEDYTOX (South Korea), Revance Therapeutic (US), DR. KORMAN PHARMA (Israel), Dermax Med (China), CGBio Co., Ltd. (South Korea), REGEN Biotech (UK), and BioScience GmbH (Germany).

Allergan Aesthetics (US):

Allergan Aesthetics (part of AbbVie) is a leading global provider in the dermal fillers market. The Juvéderm collection of dermal fillers is one of the leading products within the global dermal fillers market, alongside Galderma and Merz Pharma. Allergan Aesthetics has extensive research and development and continues to release new and enhanced filler formulations that accommodate changing aesthetic needs as well as stave off competition. Allergan Aesthetics' brand recognition, product portfolio, and commitment to education and R&D help to solidify its leading position within the aesthetics market. For example, the Allergan Medical Institute (AMI) as well as the AA Signature Program provide healthcare professionals with training, best practices, and support to achieve favorable outcomes for their patients. The resources and support provided by Allergan Aesthetics will allow for continued and potentially growing leadership to be established against a rapidly evolving and highly competitive global market in aesthetics overall.

Merz Pharma GmbH & Co. KGaA (Germany)

Merz Pharma GmbH & Co. KGaA with the Merz Aesthetics name, has a large, documented product collection of injectables, devices, and skin care products that provide the flexibility to create personalized, natural outcomes for both the face and body. The current portfolio of dermal fillers is highlighted by the Belotero family of hyaluronic acid fillers and Radiesse, the calcium hydroxylapatite filler, as well as other aesthetic solutions such as Xeomin (neuromodulator) and Ultherapy (skin tightening device). Merz invests substantially in research and development, emphasizing proprietary technologies that differentiate its fillers from competitors. For instance, Belotero utilizes Dynamic Cross-Linking Technology and Cohesive Polydensified Matrix (CPM) technology to provide predictable, enhanced, natural, and tissue-like results. Radiesse provides immediate volume as well as stimulating collagen production, which creates additional value for clients and a unique offering as the leading biostimulatory filler. Merz Pharma's continued growth in the global aesthetics market is due to robust research and development, Professional education and most importantly, a patient-focused and responsive approach.

Galderma (Switzerland)

Galderma is a pure-play category leader in dermatology, with a broad, clinically proven aesthetics portfolio, including the Restylane and Sculptra brands. Galderma's portfolio-building goals involve developing new indications for existing products (e.g., Sculptra being used for bio-stimulatory applications) and establishing new technologies for both fillers and neuromodulators. Galderma's dermal fillers strategy focuses on product innovation, commercial excellence, physician engagement, and continued international expansion. Galderma's broad, differentiated portfolio, solid clinical data, and synergistic nature of their dermatology offerings lend leadership credibility to the company, positioning them for sustained growth and continued category leadership.

For more information, Inquire Now!

Related Reports:

Dermatology Devices Market

Clinical Trial Supplies Market

Autologous Stem Cell & Non-stem Cell Therapies Market

Regenerative Medicine Market

Contract Research Organization Services Market

Get access to the latest updates on Derma Fillers Companies and Derma Fillers Market Size

About MarketsandMarkets:

MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/derma-fillers-market-worth-7-32-billion-by-2030-with-12-1-cagr--marketsandmarkets-302489375.html

© 2025 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.